Reaction

Post Transplant Lymphoproliferative Disorder reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,955 reports · 99 co-occurring drugs

As of the last recalculation, Post Transplant Lymphoproliferative Disorder appears in 4,955 FAERS reports alongside 99 co-occurring drug terms. The strongest observed disproportionality signal is TACROLIMUS OINTMENT 0.1% (PRR 233.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Tacrolimus Ointment 0.1%	2,896	233.7	239.3
Tacrolimus Extended-Release Capsules	2,896	233.0	238.6
Tacrolimus	3,045	210.3	214.4
Mycophenolate Mofetil	2,253	126.9	129.1
Mycophenolate Mofetil Hydrochloride	2,254	126.8	129.0
Ganciclovir	264	114.4	117.4
Ganciclovir Sodium	267	112.0	114.8
Anti-Thymocyte Globulin (Rabbit)	200	108.5	111.2
Basiliximab	257	96.8	98.9
Mycophenilic Acid	388	85.2	86.9
Sirolimus	231	75.5	76.8
Busulfan	265	74.7	76.0
Alemtuzumab	311	72.0	73.2
Everolimus Tablets	258	68.1	69.2
Fludarabine Phosphate	543	65.0	65.9
Valganciclovir Hydrochloride Powder,	176	62.8	63.7
Mycophenolic Acid	414	59.2	60.0
Valganciclovir	212	49.3	49.9
Valganciclovir Hydrochloride	212	49.3	49.9
Melphalan	218	42.1	42.5
Thiotepa	89	39.8	40.2
Melphalan Hydrochloride	226	39.6	40.0
Cyclosporine	830	37.4	37.7
Azathioprine	547	29.2	29.4
Prednisolone	957	27.4	27.5
Prednisolone Oral	957	27.4	27.5
Prednisolone Oral Solution	957	27.4	27.5
Vincristine Sulfate	160	23.7	23.8
Methylprednisolone	657	22.9	23.0
Rituximab	936	22.7	22.8
Everolimus	259	22.5	22.6
Cyclophosphamide Injection, Solution	783	21.9	22.0
Cyclophosphamide	783	21.9	22.0
Cyclophosphamide For Injection	783	21.9	22.0
Prednisone	1,691	20.9	21.0
Doxorubicin	345	17.4	17.5
Voriconazole Injection	71	13.9	14.0
Anakinra	53	13.6	13.6
Cytarabine	175	12.6	12.7
Brentuximab Vedotin	30	12.4	12.4
Micafungin Sodium	24	11.9	12.0
Doxorubicin Hydrochloride	88	11.5	11.5
Itraconazole	31	11.2	11.2
Amphotericin B	33	11.1	11.2
Etoposide	183	10.8	10.8
Voriconazole	73	10.2	10.3
Mesna Injection	17	8.7	8.7
Acyclovir	226	8.7	8.7
Axicabtagene Ciloleucel	20	8.5	8.6
Mesna	17	8.5	8.5
Methylprednisolone Sodium Succinate	91	8.4	8.4
Polatuzumab Vedotin	19	8.2	8.2
Human Immunoglobulin G	40	8.2	8.2
Ifosfamide	40	7.9	7.9
Tranexamic Acid	14	6.6	6.6
Bendamustine Hcl	23	6.3	6.3
Posaconazole Delayed-Release	15	5.8	5.8
Valacyclovir	53	5.4	5.4
Hydrocortisone Sodium Succinate	12	5.4	5.4
Nebivolol	20	5.3	5.3
Filgrastim	47	5.3	5.3
Meropenem	40	5.3	5.3
Nystatin Ointment	31	5.0	5.0
Nystatin Cream	31	5.0	5.0
Cefepime Hydrochloride	19	5.0	5.0
Azacitidine For	21	4.9	4.9
Nystatin	31	4.8	4.8
Mercaptopurine	19	4.6	4.6
Fluconazole	76	4.6	4.6
Prednisolone Acetate	11	4.5	4.5
Granisetron Hydrochloride	11	4.4	4.4
Methotrexate	404	4.3	4.3
Rifampicin	10	4.2	4.2
Posaconazole	16	4.1	4.1
Ursosiol	19	4.1	4.1
Cefepime	14	4.1	4.1
Gemcitabine	38	4.1	4.1
Methotrexate Sodium	436	4.0	4.0
Gemcitabine Hydrochloride	47	3.7	3.7
Ursodiol	19	3.7	3.7
Sucralfate Oral	12	3.6	3.6
Sucralfate Oral Suspension	12	3.5	3.5
Bleomycin Sulfate	8	3.3	3.3
Valacyclovir Hydrochloride	54	3.2	3.2
Bendamustine Hydrochloride	9	3.2	3.2
Azacitidine	22	3.1	3.1
Ruxolitinib	51	3.0	3.0
Blinatumomab	7	2.8	2.8
Norepinephrine	7	2.8	2.8
Dexamethasone 1.5 Mg	178	2.6	2.6
Hydroxyurea	13	2.6	2.6
Dexamethasone	178	2.6	2.6
Eltrombopag Olamine	14	2.6	2.6
Nebivolol Hydrochloride	20	2.5	2.5
Imatinib	10	2.4	2.4
Obinutuzumab	9	2.3	2.3
Remdesivir	6	1.9	1.9
Bortezomib	37	1.7	1.7
Trametinib	10	1.7	1.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.